Dirk Hondmann, Ph.D., CEO
Boston, MA
At PeterBio we develop innovative gene and cell therapies with a profound impact on people’s lives. We focus on gene-editing using our RITDM™ technology. Our RITDM™ technology is a new way of approaching gene-editing and is based on the insight that during normal cell division the DNA replication fork exposes short stretches of single stranded DNA to which complementary correction templates can bind. The cell’s own DNA repair processes can use these correction templates to generate daughter cells with the desired DNA change. A major benefit of our technology is that gene-editing can occur without the need to create DNA breaks, significantly reducing the risk of unintended changes in the genome. We make gene-editing safe enough that it can be used for a wide range of therapeutic applications.

By using this website you agree to accept our Privacy Policy and Terms & Conditions